Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This archive contains podcasts more than six months old. Find our most recent episodes at UpToDate Talk clinical podcasts or, to be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes.
Choice of basal insulin for management of diabetes; Evaluation of children with febrile seizures
Date Released: Oct 18 2017
In this episode, Dr. David Nathan discusses choice of basal insulin for management of type 1 and type 2 diabetes, and Dr. Douglas Nordli, Jr., discusses evaluation of children with febrile seizures. Dr. Nancy Sokol hosts.
Dr. David Nathan is a Professor of Medicine at Harvard Medical School and Director of the Diabetes Center at Massachusetts General Hospital in Boston.
Dr. Douglas Nordli is a Professor of Clinical Neurology and Vice Chair of Neurology at the University of Southern California Keck School of Medicine, and Chief of Pediatric Neurology at Children's Hospital Los Angeles.Segment on empagliflozin (Dr. Nathan):
- Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318:33.
- Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318:45.
Segment on febrile seizures (Dr. Nordli):
- Guedj R, Chappuy H, Titomanlio L, et al. Do All Children Who Present With a Complex Febrile Seizure Need a Lumbar Puncture? Ann Emerg Med 2017; 70:52.
David M Nathan, MD Nothing to disclose
Douglas R Nordli, Jr, MD Nothing to disclose
Guselkumab and tildrakizumab for plaque psoriasis; Two new investigational therapies for hemophilia
Date Released: Oct 4 2017
This episode features Dr. Kristina Callis Duffin discussing the efficacy and safety of guselkumab and tildrakizumab in patients with moderate to severe plaque psoriasis, and Dr. Amy Shapiro discussing emicizumab prophylaxis in hemophilia A with inhibitors and targeting of antithrombin in hemophilia A or B using RNA interference therapy. Dr. Jennifer Tirnauer hosts.
Dr. Kristina Callis Duffin is Associate Professor of Dermatology and Vice Chair of Clinical Research at the University of Utah.
Dr. Amy Shapiro is Medical Director of the Indiana Hemophilia and Thrombosis Center and Adjunct Professor of Pediatrics at Michigan State University.Segment on guselkumab and tildrakizumab for plaque psoriasis (Dr. Callis Duffin):
- Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405.
- Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418.
- Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390:276.
Segment on two new investigational therapies for hemophilia (Dr. Shapiro):
- Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377:809.
- Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med 2017; 377:819.
- http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1039464 (Accessed on September 07, 2017).
Kristina Callis Duffin, MD Grant/Research/Clinical Trial Support: Amgen [Psoriasis (Etanercept and brodalumab)]; AbbVie Inc. [Psoriasis (Adalimumab)]; Celgene Corporation [Psoriasis (Apremilast)]; Eli Lilly and Company [Psoriasis (Ixekizumab and baricitinib)]; Novartis [Psoriasis (Secukinumab)]; Bristol-Myers Squibb Company [Psoriasis (Abatacept)]; Pfizer Inc. [Psoriasis (Tofacitinib)]; Janssen Pharmaceutica [Psoriasis (Ustekinumab, guselkumab, golimumab, and infliximab)]; Stiefel Laboratories [Psoriasis (Calcipotriene)]. Consultant/Advisory Boards: Amgen [Psoriasis (Etanercept and brodalumab)]; AbbVie Inc. [Psoriasis (Adalimumab)]; Celgene Corporation [Psoriasis (Apremilast)]; Eli Lilly and Company [Psoriasis (Ixekizumab and baricitinib)]; Novartis [Psoriasis (Secukinumab)]; Bristol-Myers Squibb Company [Psoriasis (Abatacept)]; Pfizer Inc. [Psoriasis (Tofacitinib)]; Janssen Pharmaceutica [Psoriasis (Ustekinumab, guselkumab, golimumab, and infliximab)]; Stiefel Laboratories [Psoriasis (Calcipotriene)].
Amy D Shapiro, MD Nothing to disclose
Revised follow-up for solitary pulmonary nodule; Safe sleep practices and SIDS
Date Released: Sep 20 2017
This podcast features Dr. Steven Weinberger, discussing new guidelines on the management of solitary pulmonary nodules, and Dr. Michael Corwin, discussing interventions to promote safe sleep practices for infants and decrease the incidence of sudden infant death syndrome (SIDS). Dr. Nancy Sokol hosts.
Dr. Steven Weinberger is an Adjunct Professor of Medicine at the University of Pennsylvania School of Medicine.
Dr. Michael Corwin is Associate Professor of Pediatrics and Epidemiology at the Boston University Schools of Medicine and Public Health.Segment on solitary pulmonary nodule (Dr. Weinberger):
- MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017; 284:228.
Segment on SIDS prevention (Dr. Corwin):
- Doering JJ, Salm Ward TC. The Interface Among Poverty, Air Mattress Industry Trends, Policy, and Infant Safety. Am J Public Health 2017; 107:945.
- Moon RY. Air Mattresses Are Not Appropriate Sleep Spaces for Infants. Am J Public Health 2017; 107:838.
Steven E Weinberger, MD Nothing to disclose
Michael J Corwin, MD Nothing to disclose
Sentinel lymph node metastasis in melanoma; Transcranial electrical stimulation for depression
Date Released: Sep 6 2017
This episode features Dr. Michael Atkins, discussing the management of positive sentinel lymph nodes in patients with cutaneous melanoma, and Dr. Peter Roy-Byrne, discussing an investigational transcranial therapy for individuals with depression. Dr. April Eichler hosts.
Dr. Michael Atkins is Scholl Professor and Vice Chair of Medical Oncology at Georgetown University Medical Center and Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C.
Dr. Peter Roy-Byrne is Professor Emeritus in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle.Segment on management of a positive sentinel lymph node biopsy in patients with cutaneous melanoma (Dr. Michael Atkins):
- Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211.
Segment on transcranial direct current stimulation for depression (Dr. Peter Roy-Byrne):
- Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med 2017; 376:2523.
Michael B Atkins, MD Consultant/Advisory Boards: BMS; Merck; Novartis; Pfizer; Roche; Exelixis; Eisai [Melanoma; RCC; immunotherapy (Everoliumus, pazopanib; dabrafenib/trametinib; axitinib, sunitinib, avelumab; vemurafenib/cobimetinib, atezolizumab; ipilimumab/nivolumab; pembrolizumab, interferon; cabozantinib; lenvatinib)].
Peter P Roy-Byrne, MD Employment: Mass Medical Society (journal Watch); Wiley Lliss (Depression and Anxiety) [Editor in Chief]. Stock Options: Valant Medical Solutions [behavioral health (EMR)].